Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by OS Therapies

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
Tickers OSTX
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Clarifies CUSIP of Common Stock
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence
From OS Therapies
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.